Angelic Acid Prevents RANKL-Induced Osteoclastogenesis Through Pathway-Biased Inhibition of MAPK-NFATc1 Signaling.

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Excessive osteoclast activity contributes to bone loss in conditions such as osteoporosis, rheumatoid arthritis, and periodontitis.
• Natural compounds are explored for therapeutic potential due to safety, but often lack specific mechanisms.
• Targeting specific signaling pathways offers a more precise therapeutic approach for osteolytic diseases.

Purpose of the Study:

• To investigate the inhibitory effects of angelic acid (AA) on osteoclastogenesis.
• To elucidate the underlying molecular mechanism of AA's action on RANKL-induced osteoclast formation.
• To evaluate AA as a potential therapeutic agent for inflammatory bone loss.

Main Methods:

• Osteoclast differentiation assays were performed using RANKL stimulation.
• Cell viability was assessed to determine cytotoxicity.
• Western blotting was used to analyze protein phosphorylation (MAPK pathways).
• NF-κB transcriptional activity was measured.
• Nuclear translocation of NFATc1 was monitored.
• Quantitative PCR was employed to assess the expression of osteoclast-specific genes (TRAP, cathepsin K, Atp6v0d2).

Main Results:

• Angelic acid (AA) potently inhibited RANKL-induced osteoclastogenesis with an IC50 of 1.9 µM.
• AA treatment did not exhibit cytotoxicity.
• AA selectively suppressed the phosphorylation of ERK1/2, p38, and JNK (MAPK pathways) without affecting NF-κB activity.
• AA disrupted NFATc1 nuclear translocation.
• The expression of key osteoclast genes (TRAP, cathepsin K, Atp6v0d2) was reduced by AA.

Conclusions:

• Angelic acid is a novel inhibitor of the RANKL-MAPK-NFATc1 signaling axis.
• AA's mechanism involves preferential suppression of MAPK signaling, leading to impaired osteoclastogenesis.
• These findings support the therapeutic development of angelic acid for osteoporosis and other osteolytic bone diseases.